Abstract:Abstract Introduction/Objective Acute myeloid leukemia (AML) with t(16;21)(q24;q22), CBFA2T3::RUNX1 is an uncommon entity that has been reported in both pediatric and adult patients as de novo AML or secondary to prior chemo/radiation therapy. CBFA2T3::RUNX1 AMLs share similar clinico-pathological features and gene expression profile with RUNX1::RUNX1T1 AML. Methods/Case Report We report a case of AML with CBFA2T3::RUNX1 in a 52 year old female who had history of small cell cervical cancer treated with chemotherapy (4 cycles of cisplatin and etoposide) and pelvic radiation therapy. About 17 months after completion of therapy, she presented with anemia and thrombocytopenia, normal WBC/neutrophil count, eosinophilia and increased blasts (up to 10%) in blood. Bone marrow biopsy shows AML with maturation (FAB-M2), erythropoiesis is present, whereas megakaryocytes are decreased. Flow cytometry analysis shows myeloblasts with aberrant CD19 and CD56 expression; in addition, increased CD117/tryptase positive cells are noted, mostly interstitial and more concentrated around bone trabeculae. By immunohistochemical stains, these cells are at least partially positive for CD25, negative CD2, CD30. Karyotype studies demonstrate t(16;21)(q24;q22) and trisomy 8 in all metaphases. FoundationOne heme NGS studies confirmed CBFA2T3::RUNX1 fusion, and no additional mutations were identified. Patient received induction chemotherapy with Idarubicin/Cytarabine plus GO (Gemtuzumab ozogamicin); day 14 bone marrow showed chemotherapeutic effect and she is now in morphologic remission 5 months after diagnosis. Results (if a Case Study enter NA) NA Conclusion Our case adds to the limited knowledge of CBFA2T3::RUNX1 AMLs. Our case shows morphological and immunophenotypic features similar to AML with RUNX1::RUNX1T1, with unusual presentation of peripheral eosinophilia, and increased CD117/tryptase positive cells in bone marrow, the latter has been reported occasionally in core binding factor AMLs. We emphasize the importance of comprehensive genetic studies in AML patients, lack of adverse genetic abnormalities in our patient indicates favorable risk category regardless of the post-treatment clinical setting.

Systemic mastocytosis with an associated hematological neoplasm (acute myeloid leukaemia with RUNX1::RUNX1T1 fusion) – A case study

Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with RUNX1::RUNX1T1

Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation

A Multicenter Retrospective Comparison Between Systemic Mastocytosis with T(8;21) AML and KIT Mutant T(8;21) AML.

Systemic Mastocytosis Mimicking Blastic Plasmacytoid Dendritic Cell Neoplasm: a Case Report

Systemic Mastocytosis with Recurrent Anaphylactic Shock and Multiple Organ Dysfunction Failure

Diagnosis of systemic mastocytosis with cryptic deletion of TET2 and DNMT3A resulting from unbalanced translocation

Acute Myeloid Leukemia with T(8;21)(q22;q22.1)/runx1-Runx1t1 and KIT Exon 8 Mutation is Associated with Characteristic Mastocytosis and Dismal Outcomes

Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity

The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients

Systemic Mastocytosis With Associated Myeloproliferative Neoplasm With T(8;19)(P12;Q13.1) And Abnormality Of Fgfr1: Report Of A Unique Case

Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management

Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management

Acute myeloid leukemia with t(16;21)(q24;q22), CBFA2T3::RUNX1, in post-treatment setting, a case report

How I diagnose systemic mastocytosis

A multi-center retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML

Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management

Myeloid Tumors Accompanying Systemic Mastocytosis, Basophilia, and Abnormal Platelet-Derived Growth Factor Receptor Β

A primary pediatric acute myelomonocytic leukemia with t(3;21)(q26;q22): A case report

Diffuse Large B Cell Lymphoma Coexistence with Systemic Mastocytosis

MASTering systemic mastocytosis: Lessons learned from a large patient cohort